Q32 BioQTTB
QTTB
About: Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
Employees: 42
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
238% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 8
181% more capital invested
Capital invested by funds: $144M [Q2] → $406M (+$262M) [Q3]
125% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 8
33% more funds holding
Funds holding: 54 [Q2] → 72 (+18) [Q3]
7.93% more ownership
Funds ownership: 67.63% [Q2] → 75.56% (+7.93%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
165%
upside
Avg. target
$18.17
434%
upside
High target
$22
547%
upside
6 analyst ratings
4 positive
67%
2 neutral
33%
0 negative
0%
BMO Capital Etzer Darout 22% 1-year accuracy 9 / 41 met price target | 547%upside $22 | Outperform Maintained | 12 Dec 2024 |
Oppenheimer Jay Olson 22% 1-year accuracy 23 / 104 met price target | 488%upside $20 | Outperform Maintained | 11 Dec 2024 |
Piper Sandler Christopher Raymond 13% 1-year accuracy 4 / 30 met price target | 488%upside $20 | Overweight Maintained | 11 Dec 2024 |
Wells Fargo Derek Archila 42% 1-year accuracy 15 / 36 met price target | 371%upside $16 | Equal-Weight Downgraded | 11 Dec 2024 |
Leerink Partners Thomas Smith 0% 1-year accuracy 0 / 5 met price target | 165%upside $9 | Market Perform Downgraded | 11 Dec 2024 |
Financial journalist opinion
Positive
Zacks Investment Research
2 weeks ago
Q32 Bio (QTTB) Upgraded to Buy: What Does It Mean for the Stock?
Q32 Bio (QTTB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Negative
Zacks Investment Research
1 month ago
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday
Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema.
Negative
Benzinga
1 month ago
Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?
On Wednesday, Q32 Bio Inc. QTTB revealed topline results from the SIGNAL-AA Phase 2a signal finding trial evaluating bempikibart (ADX-914) for alopecia areata (AA).
Negative
Investors Business Daily
1 month ago
Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Treatment
Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record low. The post Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Treatment appeared first on Investor's Business Daily.
Neutral
PRNewsWire
1 month ago
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program
-- SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 response -- -- SIGNAL-AD Phase 2a clinical trial in atopic dermatitis demonstrated promising findings in Part A but did not meet primary endpoint in Part B -- -- Across both trials, bempikibart was observed to be safe and well tolerated; demonstrated potent IL-7 and TSLP inhibition via changes in both Th2 biomarkers and T-cells, and desired target engagement -- -- Based on these results, Company plans to advance bempikibart in patients with AA -- WALTHAM, Mass. , Dec. 10, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart (ADX-914), which identified encouraging clinical activity in patients with alopecia areata (AA).
Neutral
PRNewsWire
2 months ago
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and alopecia areata (AA) remain on-track for Q4'24, with topline data from both trials expected in December -- -- Enrollment ongoing in ADX-097 Phase 2 basket trial for complement mediated renal diseases, with topline data expected in 2H'25 and initial open-label data in 1H'25 -- -- Cash and cash equivalents of $89.1 million as of September 30, 2024 expected to provide financial runway through four Phase 2 clinical milestones and into mid-2026 -- WALTHAM, Mass. , Nov. 7, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the quarter ended September 30, 2024, and provided recent corporate updates.
Neutral
PRNewsWire
2 months ago
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
WALTHAM, Mass. , Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a fireside chat at 10:00 a.m.
Neutral
PRNewsWire
3 months ago
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024
-- Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued clinical advancement of ADX-097 -- WALTHAM, Mass. , Oct. 14, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that it will present clinical data supporting its program for innate immunity, ADX-097, at the American Society of Nephrology (ASN) Kidney Week 2024, taking place October 24-27, 2024, in San Diego, Calif.
Neutral
PRNewsWire
4 months ago
Q32 Bio to Participate in Upcoming September Investor Conferences
WALTHAM, Mass. , Aug. 29, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in three upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Thursday, September 5, 2024 Location: New York, NY 2024 Cantor Fitzgerald Global Healthcare Conference Date: Tuesday, September 17, 2024 Presentation Time: 3:40 p.m.
Positive
Seeking Alpha
4 months ago
Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097
Q32 Bio's Bempikibart and ADX-097 are in Phase 2 trials, targeting autoimmune and inflammatory diseases, with significant potential to address unmet medical needs. The company's unique approach of localized inhibition minimizes side effects and enhances efficacy, differentiating it in the biotech sector. Despite a short cash runway, Q32 Bio's recent merger, strategic reacquisition, and $42 million private placement bolstered its financial position.
Charts implemented using Lightweight Charts™